PAOG To Expand CBD Nutraceutical Sales In 2022 And Continue Pharmaceuticals Development
Sandusky, OH, Feb. 01, 2022 (GLOBE NEWSWIRE) -- PAO Group, Inc. (OTC Pink: PAOG) today republished its 2022 strategic update on the companys CBD pharmaceutical and nutraceutical development strategy.
- Sandusky, OH, Feb. 01, 2022 (GLOBE NEWSWIRE) -- PAO Group, Inc. (OTC Pink: PAOG) today republished its 2022 strategic update on the companys CBD pharmaceutical and nutraceutical development strategy.
- PAOG has positioned itself as an emerging CBD Biopharma company on a development path to treat various and major respiratory diseases that represent billions in potential market sizes.
- PAOG has also recently announced the development of a new line of CBD nutraceutical products for Puration, Inc. (OTC Pink: PURA) now underway.
- PAOG also expects to make a strategic announcement with PURA regarding a new partnership on CBD nutraceutical production resources.